Effect of High-Flow Nasal Cannula on Sleep-disordered Breathing and Sleep Quality in Patients With Acute Stroke

Nakanishi, Nobuto; Suzuki, Yasuhiro; Ishihara, Manabu; Ueno, Yoshitoyo; Tane, Natsuki; Tsunano, Yumiko; Itagaki, Taiga; Oto, Jun

doi:10.7759/cureus.9303

Cited by 2 publications

(1 citation statement)

References 28 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their study, the median sleep efficiency was 55.9%, and the 91% TST was predominantly occupied by shallow sleep of stage N1 and N2 at an HFNC flow rate of 50 L / min. In addition, HFNC at a high flow rate of 40 to 60 L / min was poorly tolerated (8,26,27). Anxiety and discomfort associated with nasal cannula, a high flow and high temperature of humid gases, noise exposure, and condensation that accumulated in the nasal prong and spraying into patient's nostril may all disrupt a patient's sleep (9)(10)(11)(12).…”

Section: Discussionmentioning

confidence: 99%

The quality and quantity of sleep on dexmedetomidine during high-flow nasal cannula oxygen therapy in critically ill patients

et al. 2022

View full text Add to dashboard Cite

Purpose : High-flow nasal cannula oxygen therapy (HFNC) is a new type of non-invasive respiratory support for acute respiratory failure patients. However, patients receiving HFNC often develop sleep disturbances. We therefore examined whether dexmedetomidine could preserve the sleep characteristics in patients who underwent HFNC. Patients and Methods : This was a pilot, randomized controlled study. We assigned critically ill patients treated with HFNC to receive dexmedetomidine (0.2 to 0.7 µg / kg / h, DEX group) or not (non-DEX group) at night (9:00 p.m. to 6:00 a.m.). Polysomnograms were monitored during the study period. The primary outcomes were total sleep time (TST), sleep efficiency and duration of stage 2 non-rapid eye movement (stage N2) sleep. Results : Of the 28 patients who underwent randomization, 24 were included in the final analysis (12 patients per group). Dexmedetomidine increased the TST (369 min vs. 119 min, p = 0.024) and sleep efficiency (68% vs. 22%, P = 0.024). The duration of stage N2 was increased in the DEX group compared with the non-DEX group, but this finding did not reach statistical significance. The incidences of respiratory depression and hemodynamic instability were similar between the two groups. Conclusions : In critically ill patients who underwent HFNC, dexmedetomidine may optimize the sleep quantity without any adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

The quality and quantity of sleep on dexmedetomidine during high-flow nasal cannula oxygen therapy in critically ill patients

et al. 2022

View full text Add to dashboard Cite

show abstract

Impact of mini-dose dexmedetomidine supplemented analgesia on sleep structure in patients at high risk of obstructive sleep apnea: a pilot trial

Sun,

Liang,

Chen

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

BackgroundObstructive sleep apnea (OSA) is common in surgical patients and associated with worse perioperative outcomes.ObjectivesTo investigate the effect of mini-dose dexmedetomidine supplemented analgesia on postoperative sleep quality pattern in patients at high risk of OSA.DesignA pilot randomized, double-blind, placebo-controlled trial.SettingA tertiary university hospital in Beijing, China.PatientsOne hundred and fifty-two adult patients who had a STOP-Bang score ≥3 and a serum bicarbonate level ≥28 mmol/L and were scheduled for major noncardiac surgery between 29 January 2021 and 20 September 2022.InterventionAfter surgery, patients were provided with high-flow nasal cannula and randomized in a 1:1 ratio to receive self-controlled opioid analgesia supplemented with either mini-dose dexmedetomidine (median 0.02 μg/kg/h) or placebo. We monitored polysomnogram from 9:00 pm to 6:00 am during the first night.Main outcome measuresOur primary outcome was the percentage of stage 2 non-rapid eye movement (N2) sleep. Secondary and exploratory outcomes included other postoperative sleep structure parameters, sleep-respiratory parameters, and subjective sleep quality (Richards-Campbell Sleep Questionnaire; 0–100 score range, higher score better).ResultsAll 152 patients were included in intention-to-treat analysis; 123 patients were included in sleep structure analysis. Mini-dose dexmedetomidine supplemented analgesia increased the percentage of stage N2 sleep (median difference, 10%; 95% CI, 1 to 21%; p = 0.029); it also decreased the percentage of stage N1 sleep (median difference, −10%; 95% CI, −20% to −1%; p = 0.042). Other sleep structure and sleep-respiratory parameters did not differ significantly between the two groups. Subjective sleep quality was slightly improved with dexmedetomidine on the night of surgery, but not statistically significant (median difference, 6; 95% CI, 0 to 13; p = 0.060). Adverse events were similar between groups.ConclusionAmong patients at high risk of OSA who underwent noncardiac surgery, mini-dose dexmedetomidine supplemented analgesia may improve sleep quality without increasing adverse events.Clinical trial registrationClinicaltrials.gov, identifier NCT04608331.

show abstract

Effect of High-Flow Nasal Cannula on Sleep-disordered Breathing and Sleep Quality in Patients With Acute Stroke

Cited by 2 publications

References 28 publications

The quality and quantity of sleep on dexmedetomidine during high-flow nasal cannula oxygen therapy in critically ill patients

The quality and quantity of sleep on dexmedetomidine during high-flow nasal cannula oxygen therapy in critically ill patients

Impact of mini-dose dexmedetomidine supplemented analgesia on sleep structure in patients at high risk of obstructive sleep apnea: a pilot trial

Contact Info

Product

Resources

About